Inmazeb (ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN)
Inmazeb (ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Inmazeb; Generic name: ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN; Manufacturer: Regeneron Pharmaceuticals, Inc..
| Brand name | Inmazeb |
|---|---|
| Generic name | ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN |
| Manufacturer | Regeneron Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection [see Dosage and Administration (2.2) , and Clinical Studies (14) ] . INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. ( 1 ) Limitation of Use The efficac |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended dosage of INMAZEB is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion. ( 2.1 ) Refer to the Full Prescribing Information for information on preparation and administration. ( 2.2 ) 2.1 Recommended Dosage INMAZEB is a combination of three human monoclonal antibodies co-formulated in a 1:1:1 ratio of atoltivimab, maftivimab, and odesivimab. INMAZEB is available as two diffe |
| Active ingredient(s) | ATOLTIVIMAB |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa |